Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0039-128x(74)90024-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Case report: prolonged durable clinical benefit and low toxicity from combination endocrine therapy in a patient with recurrent endometrial carcinoma.
Front Oncol
November 2023
Kelly Gynecologic Oncology Service, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Background: Endometrial carcinoma is the most common gynecologic cancer, with increasing incidence and mortality. Combination endocrine therapy comprised of tamoxifen and progestational agents has demonstrated promising results in treating recurrent disease. This case report describes the prolonged clinical benefit of treatment with tamoxifen and megestrol acetate in a woman with recurrent, metastatic endometrial endometrioid carcinoma positive for estrogen (ER) and progesterone receptors (PR).
View Article and Find Full Text PDFProgestogens in luteal support.
Horm Mol Biol Clin Investig
May 2020
Department of Obstetrics & Gynecology, Sheba Medical Center, Tel Hashomer, 52621, Israel.
Progestational agents are often prescribed to increase the clinical pregnancy rate in assisted reproduction. Progestogens affect implantation, cytokine balance, natural killer cell activity, arachidonic acid release and myometrial contractility. Progesterone production from the corpus luteum is essential for reproduction, but assisted reproductive technologies (ART) can impair luteal function.
View Article and Find Full Text PDF[Menopausal therapy: Modern view of the problem.].
Adv Gerontol
April 2020
Volgograd State Medical University, 1 pl. Pavshih bortsov, Volgograd 400131, Russian Federation, e-mail:
The steady tendency of modernity improve the average life expectancy of a man dictates the necessity of implementing the anti-aging stratege, one of the stratege for women is menopausal therapy. Currently, the protective effect of menopausal therapy for cardiovascular system has been proven up to 60 years after it's implication in treatment. MHT is rarely used in Russia, largely due to the hormonophobia of patients and doctors especially with oncological risk.
View Article and Find Full Text PDFProgestational agents for treating threatened or established preterm labour.
Cochrane Database Syst Rev
January 2014
Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, National University Hospital, 5 Lower Kent Ridge Wing, Singapore, Singapore, 119074.
Background: Prematurity is not only the leading cause of perinatal morbidity and mortality but is associated with long-term impairment. Studies of various tocolytic agents have shown mixed results with little effect in improving pregnancy duration and insufficient data to confirm a definite beneficial effect on neonatal morbidity or mortality. Progesterone is known to have an inhibitory effect on uterine contractility and is thought to play a key role in the maintenance of pregnancy until term.
View Article and Find Full Text PDF17-Hydroxyprogesterone caproate to prolong pregnancy after preterm rupture of the membranes: early termination of a double-blind, randomized clinical trial.
BMC Res Notes
December 2011
Obstetrix Medical Group, Center for Research, Quality, and Education, San Jose, CA, USA.
Background: Progestational agents may reduce the risk of preterm birth in women with various risk factors. We sought to test the hypothesis that a weekly dose of 17-hydroxyprogesterone caproate (17P) given to women with preterm rupture of the membranes (PROM) will prolong pregnancy and thereby reduce neonatal morbidity.
Methods: Double-blind, placebo-controlled randomized clinical trial.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!